Moradec
Moradec specializes in developing and providing innovative tools and services for antibody-drug conjugate (ADC) discovery and development. Their mission is to make prescreening of target antibodies against cancer cells faster and more economical, facilitating targeted cancer therapy research.
Industries
Nr. of Employees
small (1-50)
Products
Secondary antibody‑drug conjugates (2°ADCs)
Preformed secondary ADC reagents that bind primary antibodies and deliver cytotoxic payloads in cell‑based assays; available with varied payloads and cleavable or non‑cleavable linkers.
Phage‑display human Fab library
A human Fab phage‑display library used for antibody lead discovery and selection.
Recombinant sortases
Recombinant sortase enzymes for site‑specific protein ligation and conjugation workflows.
Competent cells
Prepared competent bacterial cells for cloning and library workflows.
Secondary antibody‑drug conjugates (2°ADCs)
Preformed secondary ADC reagents that bind primary antibodies and deliver cytotoxic payloads in cell‑based assays; available with varied payloads and cleavable or non‑cleavable linkers.
Phage‑display human Fab library
A human Fab phage‑display library used for antibody lead discovery and selection.
Recombinant sortases
Recombinant sortase enzymes for site‑specific protein ligation and conjugation workflows.
Competent cells
Prepared competent bacterial cells for cloning and library workflows.
Services
Library‑based selection and screening workflows to discover antibody leads using human Fab libraries.
Services to modify or optimize antibody reagents for improved assay performance or conjugation compatibility.
Development of cell‑based cytotoxicity assays and workflows to evaluate ADC activity, internalization, and payload efficacy.
Custom conjugation of proteins and antibodies to small molecules or payloads using cleavable or non‑cleavable linkers.
Preparation and supply of competent bacterial cells suitable for library work and molecular cloning workflows.
Library‑based selection and screening workflows to discover antibody leads using human Fab libraries.
Services to modify or optimize antibody reagents for improved assay performance or conjugation compatibility.
Development of cell‑based cytotoxicity assays and workflows to evaluate ADC activity, internalization, and payload efficacy.
Custom conjugation of proteins and antibodies to small molecules or payloads using cleavable or non‑cleavable linkers.
Preparation and supply of competent bacterial cells suitable for library work and molecular cloning workflows.
Expertise Areas
- Antibody‑drug conjugate screening and assay development
- Antibody and protein bioconjugation chemistry
- Phage‑display antibody discovery (human Fab libraries)
- Recombinant enzyme production for site‑specific conjugation (sortases)
Key Technologies
- Secondary antibody‑drug conjugates (2°ADCs) for screening
- Cleavable linker chemistries (endosomal/cathepsin‑cleavable)
- Non‑cleavable linker chemistries
- Cytotoxic payload classes: auristatins (MMAE/MMAF), maytansinoids (DM1), duocarmycins, PBDs, exatecan, amanitin derivatives, PNU